👀 Ones to watch: The MOST undervalued shares to buy right nowSee Undervalued Shares

Pharmamar shares jump after saying compound could treat coronavirus

Published 04/03/2020, 02:00 am
Updated 04/03/2020, 02:07 am
© Reuters.  Pharmamar shares jump after saying compound could treat coronavirus
SMSI
-
PHMR
-

March 3 (Reuters) - Shares in Pharmamar PHMR.MC rose sharply on Tuesday after the Spanish pharmaceutical company said its Aplidin therapeutic compound could be effective in treating coronavirus.

Pharmamar said Aplidin could block a protein that scientific publications have shown to be necessary for the coronavirus to reproduce and spread.

According to the company, Aplidin, which is approved for the treatment of multiple myeloma in Australia, would block the EF1A protein and make the reproduction of the virus inside the cell unfeasible.

Pharmamar plans to carry out laboratory confirmation tests during the next month, it said.

At 1457 GMT shares rose 14.8%, leading gains on the Madrid SE General Index .SMSI .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.